CoChat

Dose and Temporal Pattern of Estrogen Exposure Determines Neuroprotective Outcome in Hippocampal Neurons: Therapeutic Implications

Chen, Shuhua, Nilsen, Jon, Brinton, Roberta Diaz · 2006 · Endocrinology
Cited by 120

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

To address controversies of estrogen therapy, in vitro models of perimenopause and prevention vs. treatment modes of 17β-estradiol (E2) exposure were developed and used to assess the neuroprotective efficacy of E2 against β-amyloid-1–42 (Aβ1–42)-induced neurodegeneration in rat primary hippocampal neurons. Low E2 (10 ng/ml) exposure exerted neuroprotection in each of the perimenopausal temporal patterns, acute, continuous, and intermittent. In contrast, high E2 (200 ng/ml) was ineffective at inducing neuroprotection regardless of temporal pattern of exposure. Although high E2 alone was not toxic, neurons treated with high-dose E2 resulted in greater Aβ1–42-induced neurodegeneration. In prevention vs. treatment simulations, E2 was most effective when present before and during Aβ1–42 insult. In contrast, E2 treatment after Aβ1–42 exposure was ineffective in reversing Aβ-induced degeneration, and exacerbated Aβ1–42-induced cell death when administered after Aβ1–42 insult. We sought to determine the mechanism by which high E2 exacerbated Aβ1–42-induced neurodegeneration by investigating the impact of low vs. high E2 on Aβ1–42-induced dysregulation of calcium homeostasis. Results of these analyses indicated that low E2 significantly prevented Aβ1–42-induced rise in intracellular calcium, whereas high E2 significantly increased intracellular calcium and did not prevent Aβ1–42-induced calcium dysregulation. Therapeutic benefit resulted only from low-dose E2 exposure before, but not after, Aβ1–42-induced neurodegeneration. These data are relevant to impact of perimenopausal E2 exposure on protection against neurodegenerative insults and the use of estrogen therapy to prevent vs. treat Alzheimer’s disease. Furthermore, these data are consistent with a healthy cell bias of estrogen benefit.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/en.2006-0495

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 49

  1. Brinton, 2005, Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action, Ann NY Acad Sci, 1052, 57, 10.1196/annals.1347.005 · DOI · Paper page
  2. Zandi, 2002, Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study, JAMA, 288, 2123, 10.1001/jama.288.17.2123 · DOI · Paper page
  3. Shumaker, 2003, Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women’s Health Initiative Memory Study: a randomized controlled trial, JAMA, 289, 2651, 10.1001/jama.289.20.2651 · DOI · Paper page
  4. Brinton, 2000, The estrogen replacement therapy of the Women’s Health Initiative promotes the cellular mechanisms of memory and neuronal survival in neurons vulnerable to Alzheimer’s disease, Maturitas, 34, S35, 10.1016/S0378-5122(00)00107-9 · DOI
  5. Longcope, 1996, The endocrinology of the menopause, 47
  6. Santoro, 1996, Characterization of reproductive hormonal dynamics in the perimenopause, J Clin Endocrinol Metab, 81, 1495
  7. Buckler, 1999, The perimenopausal state and incipient ovarian failure, 47
  8. Zhao, 2004, Estrogen receptor subtypes α and β contribute to neuroprotection and increased Bcl-2 expression in primary hippocampal neurons, Brain Res, 1010, 22, 10.1016/j.brainres.2004.02.066 · DOI · Paper page
  9. Nilsen, 2003, Mechanism of estrogen-mediated neuroprotection: regulation of mitochondrial calcium and Bcl-2 expression, Proc Natl Acad Sci USA, 100, 2842, 10.1073/pnas.0438041100 · DOI · Paper page
  10. Carlson, 2001, Hormone replacement therapy and reduced cognitive decline in older women: the Cache County Study, Neurology, 57, 2210, 10.1212/WNL.57.12.2210 · DOI · Paper page
  11. Fillit, 1986, Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer’s type, Psychoneuroendocrinology, 11, 337, 10.1016/0306-4530(86)90019-3 · DOI · Paper page
  12. Henderson, 2000, Hormone therapy and the brain: a clinical perspective on the role of estrogen
  13. Yaffe, 1998, Estrogen therapy in postmenopausal women: effects on cognitive function and dementia, JAMA, 279, 688, 10.1001/jama.279.9.688 · DOI · Paper page
  14. Shumaker, 2004, Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study, JAMA, 291, 2947, 10.1001/jama.291.24.2947 · DOI · Paper page
  15. Brinton, 2001, Cellular and molecular mechanisms of estrogen regulation of memory function and neuroprotection against Alzheimer’s disease: recent insights and remaining challenges, Learn Mem, 8, 121, 10.1101/lm.39601 · DOI · Paper page
  16. Brinton, 2004, Impact of estrogen therapy on Alzheimer’s disease: a fork in the road?, CNS Drugs, 18, 405, 10.2165/00023210-200418070-00001 · DOI
  17. Singh, 1994, Ovarian steroid deprivation results in a reversible learning impairment and compromised cholinergic function in female Sprague-Dawley rats, Brain Res, 644, 305, 10.1016/0006-8993(94)91694-2 · DOI · Paper page
  18. Toran-Allerand, 2000, Estrogen as a treatment for Alzheimer disease, JAMA, 284, 307, 10.1001/jama.284.3.307 · DOI
  19. Woolley, 1999, Electrophysiological and cellular effects of estrogen on neuronal function, Crit Rev Neurobiol, 13, 1, 10.1615/CritRevNeurobiol.v13.i1.10 · DOI · Paper page
  20. Aggarwal, 2000, Estrogen replacement does not prevent the loss of choline acetyltransferase-positive cells in the basal forebrain following either neurochemical or mechanical lesions, Brain Res, 882, 75, 10.1016/S0006-8993(00)02832-8 · DOI
  21. Simpkins, 1997, Role of estrogen replacement therapy in memory enhancement and the prevention of neuronal loss associated with Alzheimer’s disease, Am J Med, 103, 19S, 10.1016/S0002-9343(97)00260-X · DOI · Paper page
  22. Sherwin, 2006, Estrogen and cognitive aging in women, Neuroscience, 138, 1021, 10.1016/j.neuroscience.2005.07.051 · DOI · Paper page
  23. Sherwin, 2005, Estrogen and memory in women: how can we reconcile the findings?, Horm Behav, 47, 371, 10.1016/j.yhbeh.2004.12.002 · DOI · Paper page
  24. Sherwin, 1988, Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women, Psychoneuroendocrinology, 13, 345, 10.1016/0306-4530(88)90060-1 · DOI · Paper page
  25. Sherwin, 2000, Oestrogen and cognitive function throughout the female lifespan, Novartis Found Symp, 230, 188
  26. Phillips, 1992, Effects of estrogen on memory function in surgically menopausal women, Psychoneuroendocrinology, 17, 485, 10.1016/0306-4530(92)90007-T · DOI · Paper page
  27. Paganini-Hill, 1994, Estrogen deficiency and risk of Alzheimer’s disease in women, Am J Epidemiol, 140, 256, 10.1093/oxfordjournals.aje.a117244 · DOI · Paper page
  28. Paganini-Hill, 1996, Oestrogen replacement therapy and Alzheimer’s disease, Br J Obstet Gynaecol, 103, 80
  29. Kawas, 1997, A prospective study of estrogen replacement therapy and the risk of developing Alzheimer’s disease: the Baltimore Longitudinal Study of Aging, Neurology, 48, 1517, 10.1212/WNL.48.6.1517 · DOI · Paper page
  30. Tang, 1996, Effect of oestrogen during menopause on risk and age at onset of Alzheimer’s disease, Lancet, 348, 429, 10.1016/S0140-6736(96)03356-9 · DOI · Paper page
  31. Adams, 2001, N-methyl-d-aspartate receptor mRNA levels change during reproductive senescence in the hippocampus of female rats, Exp Neurol, 170, 171, 10.1006/exnr.2001.7687 · DOI
  32. Gibbs, 2000, Long-term treatment with estrogen and progesterone enhances acquisition of a spatial memory task by ovariectomized aged rats, Neurobiol Aging, 21, 107, 10.1016/S0197-4580(00)00103-2 · DOI · Paper page
  33. Woolley, 1993, Roles of estradiol and progesterone in regulation of hippocampal dendritic spine density during the estrous cycle in the rat, J Comp Neurol, 336, 293, 10.1002/cne.903360210 · DOI · Paper page
  34. Zhao, 2006, Select estrogens within the complex formulation of conjugated equine estrogens (Premarin) are protective against neurodegenerative insults: implications for a composition of estrogen therapy to promote neuronal function and prevent Alzheimer’s disease, BMC Neurosci, 7, 24, 10.1186/1471-2202-7-24 · DOI · Paper page
  35. Nilsen, 2003, Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling, Proc Natl Acad Sci USA, 100, 10506, 10.1073/pnas.1334098100 · DOI · Paper page
  36. Nilsen, 2002, Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate, Endocrinology, 143, 205, 10.1210/endo.143.1.8582 · DOI · Paper page
  37. Nilsen, 2006, Medroxyprogesterone acetate exacerbates glutamate excitotoxicity, Gynecol Endocrinol, 22, 355, 10.1080/09513590600863337 · DOI · Paper page
  38. Foster, 2002, Calcium dysregulation in the aging brain, Neuroscientist, 8, 297, 10.1177/107385840200800404 · DOI · Paper page
  39. Landfield, 1994, Increased hippocampal Ca2+ channel activity in brain aging and dementia. Hormonal and pharmacologic modulation, Ann NY Acad Sci, 747, 351, 10.1111/j.1749-6632.1994.tb44422.x · DOI
  40. Landfield, 1992, Mechanisms of neuronal death in brain aging and Alzheimer’s disease: role of endocrine-mediated calcium dyshomeostasis, J Neurobiol, 23, 1247, 10.1002/neu.480230914 · DOI · Paper page
  41. Khachaturian, 1994, Calcium hypothesis of Alzheimer’s disease and brain aging, Ann NY Acad Sci, 747, 1, 10.1111/j.1749-6632.1994.tb44398.x · DOI · Paper page
  42. LaFerla, 2002, Calcium dyshomeostasis and intracellular signalling in Alzheimer’s disease, Nat Rev Neurosci, 3, 862, 10.1038/nrn960 · DOI · Paper page
  43. Thibault, 1996, Increase in single L-type calcium channels in hippocampal neurons during aging, Science, 272, 1017, 10.1126/science.272.5264.1017 · DOI · Paper page
  44. Thibault, 1998, Calcium dysregulation in neuronal aging and Alzheimer’s disease: history and new directions, Cell Calcium, 24, 417, 10.1016/S0143-4160(98)90064-1 · DOI · Paper page
  45. Mattson, 1993, β-Amyloid precursor protein metabolites and loss of neuronal Ca2+ homeostasis in Alzheimer’s disease, Trends Neurosci, 16, 409, 10.1016/0166-2236(93)90009-B · DOI · Paper page
  46. Brewer, 2003, Age-related estradiol regulation of calcium dynamics in hippocampal neurons, 272.7
  47. Nilsen, 2002, Dual action of estrogen on glutamate-induced calcium signaling: mechanisms requiring interaction between estrogen receptors and src/mitogen activated protein kinase pathway, Brain Res, 930, 216, 10.1016/S0006-8993(02)02254-0 · DOI
  48. Murphy, 1999, Ca2+-mediated mitochondrial dysfunction and the protective effects of Bcl-2, Ann NY Acad Sci, 893, 19, 10.1111/j.1749-6632.1999.tb07815.x · DOI
  49. Murphy, 1996, Bcl-2 potentiates the maximal calcium uptake capacity of neural cell mitochondria, Proc Natl Acad Sci USA, 93, 9893, 10.1073/pnas.93.18.9893 · DOI · Paper page

Cited by

Metadata

Authors
Chen, S., Nilsen, J., & Brinton, R. D.
Venue
Endocrinology
Published
2006-11-01
Volume
147
Issue
11
Pages
5303-5313
ISSN
  • 0013-7227 (ISSN-L)
  • 1945-7170
OpenAlex
W1992571809
Cited by
120
References
2
FWCI
8.43
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.